Stockwinners Market Radar for January 20, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:27 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Amazon's (AMZN) advertising services is leveraging what the company knows better than anyone: consumers' online buying habits, The New York Times said. Ads sold by Amazon, once a limited offering at the company, can now be considered a third major pillar of its business, along with e-commerce and cloud computing, the report noted. Amazon's advertising business may be worth about $125B, and at its core are ads placed on Amazon.com by makers of toilet paper or soap that want to appear near product search results on the site, the publication added. 2. Tesla (TSLA) was cleared to begin delivering its Model 3 sedans across Europe, according to Dutch vehicle authority RDW. Deliveries should start in February and, as happened in the U.S., the first sales in Europe will be for the Model 3 Long Range Battery variant, the report notes, citing the company. 3. Netflix (NFLX) delivered a sobering warning to the world of entertainment last week, telling shareholders that, "We compete with [and lose to] Fortnite more than HBO," Tae Kim wrote in this week's edition of Barron's. Fortnite is the gaming phenomenon that has addicted teenagers and aggravated their parents, and has stolen the gaming spotlight from Electronic Arts (EA) and Activision Blizzard (ATVI), which are both down nearly 40% from last year's highs, the publication added. And while the selloff might make them attractive for the long run, the two largest independent U.S. game publishers are "likely to be dead money in the year ahead," Kim argued, given the companies' underperforming pipeline of games. 4. Comcast (CMCSA; CMCSK) subsidiary Universal's "Glass" won the long Martin Luther King Jr. holiday weekend at the box office with an estimated $47.1M, including $40.6M for the three days. Overseas, the superhero movie opened to $48.5M from 55 markets for a three-day global launch of $89.1M and $95.6M for the four days. The film earned a B CinemaScore and sports a 36% Rotten Tomatoes score. 5. Costco (COST), Illumina (ILMN), Thermo Fisher Scientific (TMO), Danaher (DHR), Agilent Technologies (A), Bio-Techne (TECH), Newmont Mining (NEM), Barrick Gold (GOLD) Kilroy Realty (KRC) and Vornado Realty Trust (VNO) saw positive mentions in Barron's, while Tencent (TCEHY) was mentioned cautiously.

13:01 EDT Clearside Biomedical extension study of PEACHTREE for Xipere shows durability - Clearside Biomedical announced that data from MAGNOLIA, an extension study of PEACHTREE, its pivotal Phase 3 trial of Xipere in patients with macular edema associated with non-infectious uveitis, was presented during the winter symposium of the American Uveitis Society in Park City, UT. MAGNOLIA followed 28 of the 96 patients who were in the Xipere treatment arm of PEACHTREE, across 22 of the clinical sites utilized in PEACHTREE, for six additional months without treatment to better understand XIPERE's long-term clinical profile. "In MAGNOLIA, 50% of XIPERE-treated subjects maintained efficacy through 36 additional weeks after their second suprachoroidal injection of XIPERE, without requiring additional treatment," Pauline Merrill, Partner at Illinois Retina Associates and Section Director of Uveitis in the Department of Ophthalmology at Rush University Medical Center, said. "In December, we submitted a new drug application to the FDA for XIPERE to treat macular edema associated with uveitis," said Clearside's Chief Medical Officer, Tom Ciulla. "The data from MAGNOLIA expands our understanding of XIPERE and continues to increase our confidence that, if approved, can become an important new treatment option for uveitic macular edema patients. We are actively preparing to introduce XIPERE to the market, should the FDA provide an approval." The most common adverse events seen in the MAGNOLIA trial included cataracts and increases in intraocular pressure and were consistent with previous trials of XIPERE. No serious adverse events were reported.